Clinical Impact of Dose Reductions and Interruptions of Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukaemia

Second (2(nd))-generation tyrosine kinase inhibitors (TKI) (dasatinib, nilotinib) are effective in patients with all phases of chronic myeloid leukaemia (CML). Dose reductions and treatment interruptions are frequently required due to toxicity, but their significance is unknown. We analysed the impa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Santos, Fabio P S, Kantarjian, Hagop, Fava, Carmen, O’Brien, Susan, Garcia-Manero, Guillermo, Ravandi, Farhad, Wierda, William, Thomas, Deborah, Shan, Jianquin, Cortes, Jorge
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4105000/
https://ncbi.nlm.nih.gov/pubmed/20553275
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08245.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados